- Sang-Gyu ParkFounder & CEO & CSO
Sang Gyu is the founder and CEO of Novelty Nobility and a senior scientist with 25 years of experience in protein and antibody research. Up to now, he has designed more than 200 antibodies and achieved hands-on knowhow in immunization and affinity maturation, which became the impetus of Novelty Nobility’s pipeline development. Sang Gyu is an incumbent professor of Pharmacy at Ajou University and received a Ph.D. in Pharmacy from Seoul National University. He currently serves as an editorial board member of Scientific Reports.
- Jin ChoChief Finance & Business Officer
Jin leads finance and business activities at Novelty Nobility. He is an experienced professional in fundraising, deal making and operations at a biotech company and is skillful at translating science into business, and vice versa. At Novelty Nobility, Jin is mostly interested in building a corporate culture that woos talented and decent people, while he himself spends most of the time in crunching numbers and reviewing contracts. He received an MBA from MIT Sloan School of Management.
- Sun-Hwa LeeHead of ADC Research Center
Sun-Hwa has approximately 30 years of bio-related research experience. Prior to her tenure at Novelty Nobility, Sun-Hwa held a variety of cross-functional drug development roles in which she led the biological aspects of small molecule & PROTAC drug discovery for therapeutics against cancer and other diseases. Sun-Hwa holds a Ph.D. from the Boston University School of Medicine and trained as a research fellow and instructor at Harvard Medical School. In her free time, she loves staying active through hiking and yoga.
- Suk-Bong HwangHead Of General Administration
Sukbong began his career in accounting in the mid 90’s and since then has worked for 25 years in general administration. He has accumulated hands-on general operation experience in many companies from start-ups to mid-sized manufacturing companies and feels rewarded through supporting the company's business successes. Trust and responsibility are his lifetime motto, and he is equipped with fatigueless physical strength and unbreakable mental health. No one has ever beaten him in drinking and golf yet.
- Gong SungHead of CMC
Gong is a biopharmaceutical expert with around two decades of experience in CMC development of antibody and protein therapeutics. Previously at Dong-A ST and CKD, he led the development of biosimilar products of second-generation EPO and wet AMD treatment, with a responsibility to submit product approval data to the South Korean regulatory authority (MFDS). He received a master’s degree from Sungkyunkwan University and is currently pursuing a doctorate degree at its graduate school. In his words, all projects currently underway at Novelty Nobility under his name are expected to be “SUCCESS”, which is what his Korean name Gong Sung means in English.
- Tae-Young NaHead of Ophthalmology Research
Taeyoung earned her Ph.D. in pathophysiology from the College of Pharmacy, Seoul National University and completed her postdoctoral training at the Seattle Children's Hospital. She has published dozens of scientific papers across various research fields that have accumulated well over 1,000 citations. Based on Taeyoung’s robust background as a research scientist, she is currently leading our Ophthalmology Research Department. While her passion for research means that she can usually be found in the lab, she also makes time to maintain a healthy work-life balance with family and friends.
- Jae-Young SongHead of Oncology Research
Jaeyoung brings over 20 years of protein research experience in new drug discovery. He holds MS and Ph.D. in Biochemistry from Rutgers, the State University of New Jersey and postdoctoral training at Memorial Sloan Kettering Cancer Center as a research associate of Howard Hughes Medical Institute. He has expertise in drug development of small molecule as well as PROTAC, and now he is extremely fascinated by ADC at Novelty Nobility. In free time, he enjoys meeting people with playing sports and remains a BIG fan of TWINS forever.